Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Zura Bio (NASDAQ:ZURA) released its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09, Zacks reports. The business had revenue of $0.00 million during the quarter.

Zura Bio Stock Up 2.0 %

ZURA stock traded up $0.03 on Thursday, hitting $1.36. 18,996 shares of the company’s stock traded hands, compared to its average volume of 368,714. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35. The stock has a fifty day moving average of $1.48 and a 200-day moving average of $2.76.

Institutional Investors Weigh In On Zura Bio

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE raised its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,222 shares of the company’s stock after buying an additional 9,966 shares during the quarter. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZURA. Guggenheim reiterated a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday. HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Oppenheimer reissued an “outperform” rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Finally, Chardan Capital reduced their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $15.00.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.